The Effect of Bitter, Umami and Sweet Tastants on Food Intake

Not Applicable

Completed

• Conditions: Obesity
• Interventions: Dietary Supplement: bitter; Dietary Supplement: umami; Dietary Supplement: sweet

• Registration Number: NCT01956838
• Lead Sponsor: Maastricht University Medical Center

Brief Summary

Rationale: The appearance of tastants in the small intestine can result in the activation of a negative feedback mechanism from different parts of the intestine to the stomach, the small intestine and to the central nervous system. These processes inhibit food processing, appetite sensations and food intake, and furthermore they increase feelings of satiety and satiation. We will investigate the effects of intraduodenal infusion of quinine 75mg (bitter), rebaudioside A 540mg (sweet), monosodium glutamate 2g (umami), a combination of these tastants (quinine, rebaudioside A, monosodium glutamate) and placebo (5 test days in total) on ad libitum food intake, satiation and in vivo release of the gut satiety peptides CCK and GLP-1.

Study design: To assess the effect of intraduodenal infusion of single ingredients and a combination of tastants (bitter, umami and sweet) on ad libitum food intake.

Secondary Objective(s):

1. To investigate the effect of intraduodenal delivery of a combination of tastants on satiation.

2. To assess the effect of intraduodenal delivery of a combination of tastants on gastrointestinal hormone release.

3. To assess the effects of the tastants quinine, rebaudioside A and monosodium glutamate on the parameters as mentioned under the primary objective, and under secondary objectives 1 and 2.

4. To compare the effects, as mentioned under the primary objective, and under secondary objectives 1 and 2, of the combination of tastants to those of the three single tastants quinine, rebaudioside A and monosodium glutamate.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09
• Study First Submitted: 2013-09-17
• Study First Submitted QC: 2013-09-30
• Study First Posted: 2013-10-08
• Primary Completion: 2014-08
• Study Completion: 2014-08
• Status Verified: 2014-10
• Last Update Submitted: 2014-10-13
• Last Update Posted: 2014-10-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Based on medical history and previous examination, no gastrointestinal complaints can be defined.
• Age between 18 and 65 years. This study will include healthy adult subjects (male and female). Women must be taking contraceptives.
• BMI between 18 and 25 kg/m2)
• Weight stable over at least the last 6 months

Exclusion Criteria

• History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
• Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing
• Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
• Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
• Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological dynamic)
• Pregnancy, lactation
• Excessive alcohol consumption (>20 alcoholic consumptions per week)
• Smoking
• Blood donation within 3 months before the study period
• Self-admitted HIV-positive state
• Weight <60kg
• Non-tasters of sweet, bitter or umami
• Evidence of MSG-hypersensitivity or Chinese restaurant syndrome

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
bitter	bitter	intraduodenal infusion of bitter tastant
Umami	umami	intraduodenal infusion of umami
sweet	sweet	intraduodenal infusion of sweet tastant
combination	umami	intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
combination	bitter	intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
combination	sweet	intraduodenal infusion of a combination of tastants (umami, bitter and sweet)

Primary Outcome Measures

Name	Time	Method
Ad libitum meal intake	5 weeks	Difference in ad libitum meal intake (as measured during ad libitum pasta meal). At end of the testday

Secondary Outcome Measures

Name	Time	Method
Gut hormones	5 weeks	Measurements in plasma levels of the gut hormones CCK, GLP-1, insulin and glucose
Satiation	5 weeks	Difference in satiation (as measured by VAS) per time point

Trial Locations

Locations (1)

Maastricht University Medical Center; 🇳🇱 Maastricht, Netherlands